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Comprehensive Cancer Control (CCC) plans address cancer burden at the state level through consolidation of activities 
and collaboration among stakeholders. Public health genomics strategies are increasingly important in prevention and 
treatment of cancer. The objectives of this study were to assess the extent to which CCC plans have incorporated 
genomics-related terms since 2005, determine which of the 3 core public health functions were fulfilled by genomics 
components, and identify facilitators of and barriers to integration of genomics.
Methods 
We reviewed 50 CCC plans in 2010 to assess use of 22 genomics-related terms. Among plans that used the term 
genetics or genomics, we examined the plan for inclusion of genomics-related goals, objectives, or strategies and 
documented the 3 core public health functions (assessment, policy development, and assurance) fulfilled by them. We 
surveyed plan coordinators about factors affecting incorporation of genomic strategies into plans.
Results 
Forty-seven of 50 (94%) plans included at least 1 genomics-related term. Thirty-two of 50 (64%) plans included at least 
1 genomics-related goal, objective, or strategy, most encompassing the core function of assurance; 6 state plans 
encompassed all 3 core functions. Plan coordinators indicated that genomics is a low priority in state public health; 
barriers to incorporation included lack of sufficient staff and funding. 
Conclusion 
Incorporation of genomic terms into state CCC plans increased from 60% in 2005 to 94% in 2010, but according to 
plan coordinators, genomics has not grown as a priority. Identification of partnerships and resources may help 
increase the priority, encourage incorporation, and guide the eventual success of public health genomics in state plans. 
Strong partnerships with state public health departments, health care providers, and the research community are 
useful for integration.
Introduction
Comprehensive Cancer Control (CCC) is a collaborative community-based approach that uses an “integrated and 
coordinated approach to reduce cancer incidence, morbidity, and mortality” (1). Genomics aids in cancer prevention, 
detection, and treatment through early recognition, intervention, and efficient treatment (2–4). Genomics refers to the 
study of the genome as a whole, including single genes and the interaction of multiple loci and the environment. Single
-gene genomic applications, such as cascade testing for Lynch syndrome, have a potential effect in cancer prevention in 
high-risk families (5). The fundamental tool of genomics — collecting family history — is a low-cost and effective 
method to identify people at increased risk and to promote evidence-based screening (5).
The 3 core functions of public health are assessment, the collection and dissemination of data; policy development, the 
creation of standards; and assurance, ensuring quality and accessibility of services (6). A survey of public health and 
laboratory officials in 2001 identified that assurance was the most common function of public health genomics (82%); 
however, the investigators predicted more balance among the 3 functions (7).
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One other review of genomic content of state CCC plans in 2005 found that 18 (60%) of the 30 existing plans contained 
genomics content, as determined by searching the plans for genomic terms; however, the way in which terms were 
used varied (8). Today, all 50 states have a CCC plan. Genomics recommendations from the US Preventive Services 
Task Force (USPSTF), Evaluation of Genomic Applications in Practice and Prevention (EGAPP), and Healthy People 
2020 have been released, and the Genetic Information Nondiscrimination Act (GINA) has been enacted (9–12). The 
effect of these developments on CCC plans is unknown.
The objectives of this study were to assess the extent to which CCC plans have incorporated genomics-related terms 
since 2005, determine which of the 3 core public health functions were fulfilled by the genomics components, and 
identify facilitators and barriers to integration of genomics.
Methods
We conducted a qualitative analysis of state CCC plans to evaluate genomics content and surveyed state CCC plan 
coordinators to ascertain factors that affect incorporation of genomics strategies into plans.
Qualitative analysis of state CCC plans
The Centers for Disease Control and Prevention, National Comprehensive Cancer Control Program (NCCCP) 
maintains a database of all CCC plans (13). All 50 state CCC plans identified on the NCCCP website as of August 15, 
2010, were analyzed for genomics content. We made no attempt to find alternative or updated versions. We excluded 
tribal government or territorial plans from the analysis to maintain consistency and allow comparison to the findings 
from Irwin et al (8). Five plans did not indicate the year in which the plan was published or scheduled to take effect; 
the start year on the remaining 45 plans ranged from 2001 to 2010. Fourteen plans did not specify a completion date, 
but 27 of the remaining 37 plans specified a completion date on or before the year 2010 (range 2005–2015). We 
included the expired plans because they were the plans of record in the NCCCP database. The Irwin study (8) did not 
identify the plans reviewed, so we could not assess overlap between the 2 studies.
We searched each CCC plan by using an automated text search function (Box). We used 7 search terms used in the 
Irwin study (8) and 15 search terms identified by the study team. Using methods described by Irwin et al (8), we 
created a narrative assessment of each plan; it described the context and depth of the genomics components. We 
tabulated use of the following 10 terms because they were common and allowed for quantitative comparison between 
plans: gene, genetics, or genomics; family history; heritability, hereditary, or heredity; BRCA, and Lynch syndrome 
or HNPCC (hereditary nonpolyposis colorectal cancer). Summaries of the context of use were recorded by the principal 
investigator (J.L.) and reviewed by another investigator (D.D.). Additionally, some states included discrete and 
actionable genomics-related goals, objectives, or strategies. If a genomics-related goal, objective, or strategy was 
identified, the goal, objective, or strategy was categorized as filling 1, 2, or all 3 of the core functions of public health 
(assessment, policy development, and assurance) as defined by the Association of State and Territorial Health Officials 
(6). Each of these items was recorded verbatim and analyzed independently by the investigators (J.L., D.D.), and 
inconsistencies were discussed until a consensus was reached. Our analysis did not order these categories 
hierarchically to maintain consistency between plans.
Survey of state CCC plan 
coordinators
We created a semiquantitative survey using the survey 
developed by Irwin et al (8) as a guide. Open-ended 
responses from the Irwin survey (eg, barriers, 
successes) were converted to multiple-choice questions 
with the option of open responses (Appendix). The 
survey also included questions about planning and 
writing of the CCC plan, implementation of genomics 
objectives, and characterization of the role and priority 
of genomics in CCC. The survey was made available 
online via Survey Monkey 
(http://www.surveymonkey.com/) or in a paper 
format. A representative from each of the states whose 
plan contained at least 1 term related to genetics or 
genomics was invited to participate in the survey. We 
collected responses during April and May 2011. The 
survey portion of this study was approved by the Wayne 
State University institutional review board.
Box. Genetics- and Genomics-
Related Terms Used To Search 
State Comprehensive Cancer 
Control Plans 
Search Terms Used By 






Family history Genetic services
DNA Relative
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We visited each state CCC website to obtain e-mails, 
addresses, and telephone numbers for state CCC plan 
representatives. If an e-mail was available, we sent an 
invitation to participate in the survey, including a link 
to the survey. If no e-mail was available, we mailed a 
packet that included a copy of the survey and 
instructions for accessing the survey online. People who 
had not yet completed the survey or declined to 
participate were contacted via telephone 2 weeks after 
the initial invitation. If no telephone contact could be 
made, an e-mail or second mailing was sent to the 
address used previously. 
We used descriptive statistics to analyze data. Percentages and responses are presented as proportions of states that 
answered each question. 
Results
Review of state CCC plans
Of the 50 state CCC plans reviewed, 47 (94%) contained at least 1 genomics-related term. Of these, most mentioned 
family history (43 of 47, 91%) and gene or genetics (40 of 47, 85%). Fewer plans mentioned genomics (11 of 47, 23%) 
or specific genetic conditions such as hereditary breast ovarian cancer or BRCA (18 of 47, 38%) or Lynch syndrome 
or HNPCC (6 of 47, 13%).
Overall, 32 of 47 states (68%) that mentioned genetics or genomics had a genomics-related objective, goal, or strategy 
(Table). These objectives, goals, and strategies had similar themes, including educating the public or health care 
providers about the importance of genetics and/or family history, collaborating with academic institutions, 
researchers, or workgroups, identifying people at risk for a genetic susceptibility to cancer, and supporting research. 
The most common goal was to increase access to genetic risk assessment services such as genetic counseling or genetic 
testing, including reimbursement for genetic risk assessment services (24 of 32, 75%). Family history was the second 
most common theme (18 of 32, 56%), including education of the public or health care providers or development of a 
family history tool. Other goals included preventing genetic discrimination (5 of 32, 16%) and encouraging research in 
the field of genetics and genomics (5 of 32, 16%).
Overall, 30 of the 32 (94%) states’ goals, objectives, or strategies fulfilled the function of assurance; 11 of the 32 (34%), 
assessment; and 12 of the 32 (37%), policy development (Table). Six states had objectives or strategies that 
encompassed all 3 core public health functions, including 3 of the 4 states that received a 5-year cooperative agreement 
with CDC from 2003 through 2008 to incorporate genome-based knowledge into disease prevention (Michigan, 
Minnesota, and Oregon). All states except Kentucky, Oklahoma, and West Virginia included at least 1 core function. 
Examples of the strategies related to assessment included assessing the effect of direct-to-consumer marketing of 
genetic test campaigns and review of health plan policies for consistency with USPSTF guidelines for BRCA counseling. 
Examples of the strategies related to policy development included advocating for third-party payment of genetic 
counseling, testing for the uninsured and underinsured, and advocating for genetic counseling state licensure. 
Examples of strategies related to assurance included provider and public education about genomics.
Plans that mentioned genomics but did not mention an objective, goal, or strategy often mentioned genomics in terms 
of genetic risk, health disparities, or health insurance discrimination. Many plans provided extensive information on 
the state’s cancer burden or cancer risk factors that included an explanation of genomics concepts. Other plans 
described family history as a risk factor for certain cancers and detailed the genetics of hereditary breast and ovarian 
cancer and Lynch syndrome.
Survey
Thirty-five of the 47 plans that included genomics-related terms were contacted via e-mail from published e-mails or e-
mails provided on initial contact by telephone, and the remaining 12 surveys were mailed to the state contact address 
published on the CDC NCCCP website (13). Twenty surveys were completed online, and 2 surveys were submitted 
through mail. Three states that completed the online survey provided only demographic information and were 
excluded from the analysis (overall response rate, 40% [19 of 47]). Fifteen respondents indicated that they were the 
states’ CCC plan manager or coordinator, 1 respondent was a designated contact person for cancer genomics, 1 
respondent was a regional chairperson, and 1 respondent did not identify a position.
Seventeen of 19 respondents identified sectors involved in the planning and writing of the CCC plan, including 
hospitals (17 of 17), support groups or advocacy organizations (17 of 17), local public health organizations (16 of 17), 
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into the CCC plan. Eleven respondents identified key facilitators for the integration of genomics concepts, including 
partnership with the health care community and research community (7 of 11) and the state department of health (5 of 
11). In an open-response question asking states to identify the organization or individual who provided the greatest 
amount of support to integration of these concepts, 4 respondents identified genetic counselors.
When asked, most respondents (10 of 18) believed that awareness of genomics increased between the years of 2000 
and 2006. However, many different events or circumstances were noted as the cause of this increase in awareness, 
including the human genome project, the identification of BRCA1/2, CDC genomics funding, the promise of gene 
therapy, and collaboration with members of the public health community, health care providers, and researchers. No 
states identified EGAPP, USPSTF recommendations, GINA, or Healthy People 2020 objectives. Eleven of 15 
respondents indicated that genomics is not a priority or somewhat not a priority, while no states rated genomics as a 
high priority. Of the 6 respondents from states that could assess the change in priority of genomics, 3 felt the priority 
had increased in the last 5 years, and 3 felt that the priority had decreased.
When asked, only 3 respondents were able to identify barriers to the implementation of genomic concepts; these 
barriers included genomics being a low priority (2 of 3), time constraints (2 of 3), lack of sufficient staff or leadership 
(2 of 3), and lack of funding (3 of 3). The low response rate to this question may be due to the fact that only 4 
respondents indicated they had implemented genomic components within the CCC plan; 3 respondents reported 
having accomplished their objectives. An open-response question asking respondents to identify partnerships and 
resources key to implementing genomic components was answered by 10 respondents; 4 identified increased funding 
and 3 identified stronger partnerships with health insurance companies and managed care agencies. Other 
respondents identified stronger partnerships with researchers, health care workers, and academia; development of 
evidence-based strategies at the national level; and examples of successful CCC plans that implement genomics 
concepts.
Discussion
Our findings on the use of genomics concepts in CCC plans are similar to those in the Irwin study: many plans focused 
on education, collaboration, and family history and risk assessment (8). Although more plans in our study used 
genomics terms than plans in the Irwin study, the scope and depth of coverage was inconsistent.
Interestingly, many plans that have goals, strategies, or objectives related to genetics or genomics focus on the core 
function of assurance (30 of 32) and less on assessment (11 of 32) and policy development (12 of 32). These core 
functions have been described as cyclical: assessment leads to policy development, and policy development results in 
assurance (6). However, the genomics-related objectives identified in our study appeared to function in reverse: for 
example, a family history tool was developed before its need was assessed. Such a lack of assessment hinders the ability 
to measure the effect of genomics interventions.
Another approach to translating genomic discoveries into population health has been described as a continuum of 4 
linear phases (14). Phase 1 translates a basic genome-based discovery into a health application; Phase 2 creates 
evidence-based guidelines; Phase 3 moves the evidence-based guidelines into practice; Phase 4 evaluates the effect on 
population health. Three percent or less of genomics research occurs in Phase 2 through 4 (14). Some have questioned 
the large amount of spending on recent genomic research and the lack of genomics-related benefits in medicine (15). 
These questions may be influencing the decreased prioritization of genomics reported by several survey respondents. 
Although only 3 respondents reported on barriers, the barriers were similar to those reported by Irwin et al (8) and by 
others examining the incorporation of evidence-based initiatives into state CCC plans; they may not be unique to 
genomics (16,17).
The strengths of this study include the finite, well-defined sample. Having access to all 50 state CCC plans through the 
CDC’s NCCCP website allowed for comprehensive analysis. The availability of contact information allowed for 
invitation and representation of all states that chose to participate. The semiquantitative survey method permitted 
objective analysis while encouraging respondents to share experiences leading to the identification of barriers and 
successes, which may guide future studies and CCC planning. Additionally, the survey allowed plan coordinators an 
opportunity to comment on their state’s upcoming revisions if a plan was about to or had expired.
This study has limitations. One limitation is that 27 out of 32 plans with a published end date were set to expire on or 
before 2010. Once plans are updated, a reanalysis should be performed, particularly because of recent genomics 
recommendations and legislation. Another limitation is that we could not assess overlap between plans used for our 
analysis and analysis by Irwin et al (8). Nonetheless, this study reflects an analysis of the current plans identified on 
the NCCCP website (13). Survey results were potentially biased because of the use of a mail and e-mail format; only 2 
mail-based surveys were returned. States that do not publish an e-mail address may not have a CCC coordinator, and 
results may represent only a subset of states. The response rate of 40% is low, especially compared with the response 
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rate of 89% for the Irwin study (8). Finally, some respondents decided not to answer a wide range of questions; this 
lack of response limited our data set.
Overall, we affirmed our hypothesis that more states are incorporating genomics into state CCC plans. However, the 
scope and depth of coverage is narrow, with many plans focusing on assurance. How the incorporation of genomics-
related concepts affects cancer control is unclear, but assessment will be crucial measuring the impact as it may take 
years to recognize the effects. USPSTF and EGAPP recommendations and Healthy People 2020 genomics-related 
objectives should serve as a baseline for integrating genomics into state CCC plans. Other chronic disease plans (eg, 
asthma, diabetes, cardiovascular disease, dementia) are being created and can also benefit from the research on the 
successes and barriers of genomics integration into CCC plans. Finally, learning from the successes and barriers of 
states may lead to standardization of language and goals for future plans, including a cohesive national CCC plan.
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Table. Comprehensive Cancer Control (CCC) Plans,  by State, Date Range, 
and Genetic/Genomic Goal, Objective, or Strategy Genetics or Genomics 
Component
State




Core Public Health Functions  
(6) 
Began Ends Assessment Policy Assurance
Alabama 2006 2010 No
Alaska 2005 2010 Yes X
Arizona NS NS No
Arkansas NS NS Yes X
California 2004 NS No
Colorado 2005 2010 Yes X
Connecticut 2005 2008 Yes X
Delaware NS NS No
Florida 2003 2006 No
Georgia 2008 2012 No
Hawaii 2004 2009 Yes X
Idaho 2006 2010 No
Illinois 2005 2010 Yes X X
Indiana 2005 2008 No
Iowa 2006 2011 Yes X X
Kansas 2005 NS No
Kentucky NS NS No
Louisiana 2004 2009 No
Maine 2006 2010 Yes X
Maryland 2004 2008 Yes X X
Massachusetts 2006 2011 Yes X X
Michigan 2009 2015 Yes X X X
Minnesota 2005 2010 Yes X X X
Mississippi 2006 2011 Yes X X X
Missouri 2004 NS No
Montana 2006 2011 Yes X
a
b
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State




Core Public Health Functions  
(6) 
Began Ends Assessment Policy Assurance
Nebraska 2004 2010 Yes X
Nevada NS NS No
New 
Hampshire
2005 2010 Yes X X
New Jersey 2008 2012 Yes X
New Mexico 2007 2011 Yes X X X
New York 2003 2010 Yes X X
North Carolina 2010 NS Yes X X
North Dakota 2006 2010 Yes X
Ohio 2006 2010 Yes X
Oklahoma 2007 NS No
Oregon 2005 2010 Yes X X X
Pennsylvania 2003 NS Yes X
Rhode Island 2007 NS No
South Carolina 2005 2010 Yes X X
South Dakota 2005 2010 Yes X
Tennessee 2009 2012 Yes X
Texas 2005 NS Yes X
Utah 2006 2011 Yes X X
Vermont 2006 2010 Yes X
Virginia 2001 2005 No
Washington 2004 2008 Yes X X X
West Virginia 2007 NS No
Wisconsin 2005 2010 Yes X
Wyoming 2006 2010 No
Abbreviation: NS, not specified. 
 Plans obtained in August 2010 (12). 
 Core functions categorize the nature of the genetic/genomic goal as assessment, assurance, or policy development based 
on definitions set forth by the Association for State and Territorial Health Officials (6). All states except Kentucky, 
Oklahoma, and West Virginia included at least 1 core function.
Appendix 
 
What state do you represent?

























Other postgraduate degree (eg, JD, MD) (Please specify):










4a. Of these groups (academia, hospitals/health care providers, private sector/industry, support groups/advocacy 
organizations, faith-based groups, local public health, media), who do you perceive as the biggest champion of 
genetics/genomics integration (please rank from lowest to highest)?











5a. How was genetics/genomics identified as a priority in public health and cancer prevention/control (such as an 
event or circumstance)?
6. Please identify all of the facilitators that were key to integration of the genetics/genomics components of the CCC 
plan
Strong partnerships within the state department of health
Strong partnerships with the health care provider community
Strong partnerships with the research community
High priority of genetics/genomics within state public health department
Genetic counselor on staff
Additional funding sources
Provision of continuing education credits for professions
Unknown/don’t know
Other (please specify):
6a. What organization or individual was your greatest source of support to implementation of genomics concepts?
7. Please describe the general process used to write the genetic/genomics section(s).




8a. What barriers have you encountered?
Lack of a strong partnership with the research/medical community
Lack of support within the department
Low priority
Lack of sufficient staff/leadership
Lack of sufficient funding
Time constraints
Misperceptions or misinformation about genetics/genomics
Lack of evidence base
Lack of demonstrable outcomes
Other (please specify):
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8b. How have you overcome these barriers?








9b. If yes, what was your greatest accomplishment to date? If possible, please include an explanation of the process 
outcomes and population impact.
9c. If no, why do you feel you have not accomplished your assigned goal/objective?
10. What is the current priority level of genomics in your state health department?
High priority
Somewhat a priority
Somewhat not a priority
Not a priority
Don’t know/Unknown





11. Have you begun the process of drafting a subsequent CCC?
Yes
No
11a. If yes, have the genetics/genomics components changed?
Yes
No
11b. Are there plans to incorporate information on specific genetic cancer syndromes (eg, Hereditary Breast and 
Ovarian Cancer Syndrome, Lynch syndrome)?
Yes
No
Incorporated into previous plan
11c. Which syndromes are being considered for incorporation in your future plan?
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Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/2)
Lynch syndrome
Other (specify):
12. What types of partnerships and resources would be helpful in further implementing the genomics components of 
your state plan?
13. What public health genomics training resources have you utilized?
 
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, 
or the authors' affiliated institutions. 
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